Onco Actu du 21 novembre 2016

	3.2 Prévention - Obésité
Weight loss may help prevent multiple myeloma [Washington University in St. Louis] The researchers analyzed data from a U.S. Department of Veterans Affairs database, identifying 7,878 patients, predominately men, diagnosed with monoclonal gammopathy of undetermined significance from October 1999 through December 2009.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
FDA puts off closing lab-test ‘loophole,’ leaving decision to Congress and Trump [STAT] After arguing for months that certain medical tests led to patients being mistakenly told they had illnesses and undergoing pointless treatment, the Obama administration Friday dropped its plans to regulate them.
	4.5 Dép., diag. & prono. - Colorectal
Quantitative faecal immunochemical tests to assess symptomatic people who are at low risk of colorectal cancer in primary care [NICE] Note that this document is not NICE's final guidance on quantitative faecal immunochemical tests. The recommendations in section 1 may change after consultation.
	4.7 Dép., diag. & prono. - Col de l'utérus
Johns Hopkins Scientists Advance a Novel Urine Test to Predict High-Risk Cervical Cancer [Johns Hopkins] “Our urine test would serve as a molecular triage,” he says, “at times supplementing Pap test information. In developing countries that don’t have the money, medical infrastructure or cultural approval for Pap test, our test could be used instead.”
	5.2 Pharma
NICE thumbs up for BMS leukaemia treatment [BMS] The decision was based on data harvested from a 260-participant Phase III trial which showed that patients treated with Sprycel demonstrated an 11% higher confirmed complete cytogenic response (cCCyR) than those treated with current standard of care imatinib (77% versus 66%).
Clovis sued over statements about lung cancer drug roci [FierceBiotech] The law firm's allegations relate to differences between data Clovis reported in May and November of last year.
Sanofi Halts Production of Bladder Cancer Drug as Others Fail to Win FDA Approval [RAPS] Sanofi said production will cease at the Canadian manufacturing facility where the treatment is made in mid-2017 and production elsewhere will not resume.
Alternative Pathways for Cancer Scientists: Careers in Industry [AACR] Depending on the individual employer, the typical workday of a scientist in industry may mirror that of one in academia—or it may seem like a world apart.
Spectrum floats new PhIII idea after FDA slaps down failed bladder cancer drug [EndPoints] Spectrum filed notice of the FDA’s rejection in an SEC filing, noting that it may try a new Phase III trial to replace another study that’s already been halted — even though the company’s web site says the recruitment is still underway.
Spectrum Pharma says U.S. FDA rejects its bladder cancer drug [Reuters] Apaziquone is being developed to treat non-muscle invasive bladder cancer, also known as early bladder cancer, which accounts for about 80 percent of all bladder cancers.
	5.2.1 Pharma - Partenariats
Celgene buys into experimental cancer med from Triphase [FierceBiotech] Celgene has acquired all of the biotech’s assets relating to its proteasome inhibitor, marizomib (MRZ), which is in development for glioblastoma (one of the most aggressive brain cancers) and relapsed and/or refractory multiple myeloma.
Cellectar Advances Drug Research With Pierre Fabre, Other Partners [Xconomy] Madison, WI-based Cellectar said Thursday that it has created multiple tumor-targeting compounds and has already started using them in a series of studies. The compounds were made using cancer-killing agents called “cytotoxics” that were developed by Pierre Fabre, a French pharmaceutical company.
	5.3 Traitements - FDA, EMA, NICE...
FDA Delays Finalization of Lab-Developed Test Draft Guidance [RAPS] Roger Klein, chair of the professional relations committee at the Association for Molecular Pathology, told Focus: "FDA's decision to delay release of a final LDT guidance is in the best interest of patients and providers, and supports further advancement in molecular pathology testing."
Regulatory information – New guidance on type II variations and marketing authorisation extensions for orphan-designated medicines [EMA] This aims to ensure that the orphan marketing authorisation only covers indications that fulfil the orphan designation criteria foreseen in the Orphan Regulation.
Adaptive pathways workshop briefing book [EMA] This document is preparatory reading material for the adaptive pathways workshop. It is meant to be a working tool to support productive discussion at the workshop.
	6.1 Observation
Childhood cancer survivors may not get needed adult care [Reuters] While plenty of previous research has documented gaps in adult follow-up care for childhood cancer survivors, the current study focused on risk factors that parents and doctors of these children may be able to change.
	6.10 Politiques
Brexit: MPs call for clear plan to protect science [Cancer Research UK] MPs sitting on the Science and Technology Committee called on Government to increase the amount of money the UK spends on science. They also said it was essential that the UK continues to attract top-quality researchers.
	6.10.1 Politiques (USA)
MD Anderson to biotech billionaire Soon-Shiong: Get your own slogan. ‘Moon Shots’ belongs to us [EndPoints] The vast Houston cancer center is not about to let some Johnny-come-lately biotech upstart like billionaire Patrick Soon-Shiong come along and take it for himself.
Dinner and a biotech chat: Billionaire Patrick Soon-Shiong talks ‘innovation’ with president-elect Trump [EndPoints] While MD Anderson has been making trouble for Patrick Soon-Shiong’s cancer moon shot campaign, the high-profile biotech billionaire has been making his case directly with president-elect Donald Trump, talking about innovation and healthcare priorities over a meal Saturday night.
MD Anderson Sues Billionaire Over Using the Word “Moonshot” [The Cancer Letter] Soon-Shiong’s corporations applied for trademark protection for three entities involved in his moonshot: Cancer Moonshot 2020, Cancer Moonshot 2020 Foundation, and Cancer Moonshot Network News. Last month, MD Anderson Cancer Center applied for trademark protection for its own moonshot program and filed an opposition to potential issuance of trademarks to Soon-Shiong, and—in a related move—sued Soon-Shiong and three of his corporate entities.
	6.11 Patients
Empower people with cancer by talking about dying [The Cancer Blog] I really hope we can encourage a society where such conversations are seen as natural and healthy. If they have such conversations, doctors will sometimes find that the right thing to do is nothing.
	6.4 Médico-éco
A&E, cancer and maternity units to close in major NHS overhaul [The Guardian] Dozens of England’s 163 acute hospitals look likely to have services, including cancer, trauma and stroke care, removed as a result of the plans, which are at the heart of the new funding package for the NHS.
	6.6 Publications
Is the peer review system sustainable? [STAT] The amount of time reviewers spend on the task is, simply put, gargantuan: an estimated 63.4 million hours in 2015 alone, according to the authors of the study, or roughly 7,300 years’ worth of reviewing. If journals were to compensate those reviewers at a reasonable rate of $75 per hour, that’s on the order of $4.5 billion of labor.
	6.9 Controverses
China Used Crispr to Fight Cancer in a Real, Live Human [Wired] The Sichuan University trial received ethical approval from a hospital review board in July, after only six months of review. “To get the same thing approved in the US would take dramatically longer,” says Paul Knoepfler, a stem cell researcher at UC Davis.